Premium
Malignancy‐associated pruritus
Author(s) -
Rowe B.,
Yosipovitch G.
Publication year - 2016
Publication title -
european journal of pain
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.305
H-Index - 109
eISSN - 1532-2149
pISSN - 1090-3801
DOI - 10.1002/ejp.760
Subject(s) - malignancy , medicine , lymphoma , dermatology , cancer , melanoma , cutaneous t cell lymphoma , pathology , mycosis fungoides , immunology , cancer research
Malignancy‐associated pruritus can be the result of a neoplasm's local effect on tissue or due to the systemic reaction to malignancy. A systemic reaction to malignancy has been termed ‘paraneoplastic itch’ and can be the first sign of an underlying malignancy. Paraneoplastic itch is most commonly caused by lymphoproliferative malignancies, and severity of itch correlates with stage of disease in Hodgkin's lymphoma and polycythemia vera. Non‐melanoma skin cancer is the most common type of malignancy‐associated pruritus, and recent data indicate that pruritus is associated with more than one‐third of non‐melanoma skin cancers. Cutaneous T‐cell lymphomas ( CTCL ), particularly more advanced stages, cause intractable pruritus and recent investigations into the pathophysiology of CTCL ‐associated itch have implicated cyotokine interleukin‐31 as a putative mediator. Treatments that reduce itch in CTCL patients, such as histone deacetylase inhibitors ( HDAC i), Mogamulizumab, a novel monoclonal antibody against chemokine receptor type‐4, and oral corticosteroids, have demonstrated a correlation between their anti‐pruritic effect and reduced serum levels of interleukin‐31.